Heart Failure

The AJMC® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.

Latest News

Blood pressure monitor | Image credit: Photo Sesaon – stock.adobe.com
Remote Monitoring Program Cuts Heart Failure Readmissions in Half

October 11th 2024

UMass Memorial Health–Harrington Hospital reduced 30-day readmissions for congestive heart failure by 50% using artificial intelligence and remote care teams.

Heart and stethoscope | Image credit: New Africa – stock.adobe.com
Optimizing GDMT Could Prevent Over 1 Million HFrEF Deaths Annually

October 2nd 2024

Heart failure | Image credit: irissca – stock.adobe.com
Adherence to 2021 ESC Heart Failure Guidelines Differed Across Practices

September 26th 2024

Hospital sign | Image credit: merrimonc – stock.adobe.com
Study Reveals High Variability in Hospital GDMT Scores, Outcomes, Costs

September 25th 2024

Pediatrician listens to child's heart | Image Credit: © Viacheslav Yakobchuk - stock.adobe.com
Sacubitril/Valsartan, Enalapril Show Comparable Efficacy in Pediatric Heart Failure

September 25th 2024

Heart Failure Clinical and Economic Burden

An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.

John McMurray screenshot
Continuing Medical Education
View All
October 13th 2024

Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction

1.0 Credits / Cardiology
October 13th 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
October 13th 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Image of data investigation
February 10th 2022

Longer-Term Elevated Cardiovascular Risks Evident From COVID-19 Infection

Maggie L. Shaw
This new analysis of more than 11 million veterans investigated risks of several cardiovascular diseases beyond the first 30 days after COVID-19 infection.
Computer generated image of a heart
February 5th 2022

Heart Failure History May Indicate Greater Risks of Cancer, Related Mortality

Maggie L. Shaw
This study from Italy investigated potential associations between heart failure and comorbid cancer and whether the existence of heart failure predisposed individuals with both to a higher risk of death.
Image of electronic patient evaluation
February 1st 2022

Overall Effectiveness of Atrial Shunt for HFpEF Remains Questionable

Maggie L. Shaw
There is a persistent lack of effective treatments for heart failure with preserved ejection fraction (HFpEF), so in this study, investigators examined the impact of an atrial shunt among patients with this disease subtype.
Red and white heart image
January 28th 2022

LV Changes, CABG Contribute to Higher Mortality Risk From Heart Failure

Maggie L. Shaw
In this new study from China, the link between left ventricular (LV) structural changes and mortality following coronary artery bypass grafting (CABG) was investigated among a patient cohort with heart failure with reduce ejection fraction.
Image of a heart and stethoscope
January 25th 2022

USPSTF Maintains AFib Screening Recommendation

Maggie L. Shaw
The US Preventive Services Task Force (USPSTF) had announced an update to its 2018 recommendation on screening for atrial fibrillation (AFib) for older adults.
Image of fast walkers
January 20th 2022

Fast Walking Pace Shown to Benefit Patients With Heart Failure

Maggie L. Shaw
These new study findings support a link between faster walking pace and reduced risk of developing heart failure and its subtypes.
Image of cardiologist holding a heart
January 19th 2022

Timely Cardiac Function Recovery Seen Among Children With COVID-19, MIS

Maggie L. Shaw
This new short-term matched study from investigators at Children’s Hospital of Philadelphia investigated cardiac-related outcomes among pediatric patients presenting with COVID-19–related multisystem inflammatory syndrome.
Image of a graphic of a broken heart
January 14th 2022

Malnutrition May Decrease Life Expectancy in Those With Heart Failure

Maggie L. Shaw
The combined effects of obesity and malnutrition among individuals with heart failure were explored in this recent study from France, with the investigators noting that while malnutrition is a risk factor for adverse outcomes, obesity often confers a protective effect.
Image of physician making heart shape with hands.jpg
January 11th 2022

Sodium Restriction May Not Benefit All Patients With Heart Failure

Maggie L. Shaw
Following a review of trials that evaluated reduced sodium intake among patients with heart failure, investigators found no improvement to patient quality of life or their risks of mortality and hospital readmission.
heart graphic
January 6th 2022

Authors Outline Potential Targeted Therapeutic Intervention for HFpEF

Gianna Melillo
Authors described recent therapeutic developments in heart failure with preserved ejection fraction (HFpEF) and proposed a conceptual framework for more targeted treatment.
diversity graphic
January 3rd 2022

Race and Sex Differences Seen in ICD Use for Hypertrophic Cardiomyopathy

Gianna Melillo
Analysis results revealed racial and sex disparities among patients with hypertrophic cardiomyopathy who receive implantable cardioverter-defibrillator (ICD) devices.
Top 5 most-read heart failure articles of 2021
December 29th 2021

Top 5 Most-Read Articles in Heart Failure for 2021

Laura Joszt, MA
In 2021, there were some changes to recommendations and an important FDA approval for patients with heart failure or who are at risk of heart disease.
Adriaan Voors, MD, University Medical Center Groningen, the Netherlands
December 24th 2021

Dr Adriaan Voors: Health Care Reimbursement May Affect SGLT2 Inhibitor Uptake

Mary Caffrey Maggie L. Shaw
Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, explains why patients provided sodium-glucose co-transporter 2 (SGLT2) inhibitors in hospitals may be unable to continue the medication after discharge.
Heartbeat
December 19th 2021

Expanded Label of Sacubitril/Valsartan for HF Could Drastically Expand Eligible Population

Laura Joszt, MA
Under the expanded FDA label, up to 1.8 million individuals in the United States could be eligible for sacubitril/valsartan, and up to 180,000 worsening heart failure (HF) events could be prevented or postponed.
Adriaan Voors, MD, University Medical Center Groningen, the Netherlands
December 18th 2021

Dr Adriaan Voors on Possible Unexplained Benefits of SGLT2 Inhibitors

Mary Caffrey Maggie L. Shaw
Adriaan Voors, MD, University Medical Center Groningen, the Netherlands, discusses how and why sodium-glucose co-transporter 2 (SGLT2) inhibitors act so quickly for patients with heart failure.
Stethoscope and heart
December 9th 2021

Investigators Ask if COVID-19 Infection Is to Blame for Cardiac Dysfunction

Maggie L. Shaw
Findings presented today during EuroEcho 2021 demonstrate a potential link between persistent dyspnea following recovery from COVID-19 infection and subclinical cardiac dysfunction.
Hands gently holding heart
December 7th 2021

Novel Heart Failure Rehab Intervention May Hold Economic Value in the Longer Term

Maggie L. Shaw
A secondary analysis of economic outcomes–related data from the Rehabilitation Therapy in Older Acute Heart Failure Patients trial attempted to answer if a novel 12-week rehabilitation intervention held cost-effective value.
Site Logo
December 3rd 2021

Variation in Early Diffusion of Sacubitril/Valsartan and Implications for Understanding Novel Drug Diffusion

Lauren Gilstrap, MD, MPH Ashleigh King, MPH Stephanie Tomlin, MS, MPA Andrea M. Austin, PhD
Rates of sacubitril/valsartan diffusion have been slow and there has been significant geographic variation, highlighting the importance of local prescribing patterns in early drug diffusion.
Adriaan Voors, MD,University Medical Center Groningen, the Netherlands
December 2nd 2021

Dr Adriaan Voors Explains Potential Decongestive Benefits of Empagliflozin

Mary Caffrey Maggie L. Shaw
Adriaan Voors, MD, discusses possible mechanisms of action of empagliflozin that produce such beneficial results among patients with heart failure, in an interview about the EMPULSE trial prior to this year’s American Heart Association Scientific Sessions.
SGLT2 Inhibitors Show Success Against HFpEF in New UK Study
December 1st 2021

SGLT2 Inhibitors Show Success Against HFpEF in New UK Study

Maggie L. Shaw
This new investigation into the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors for heart failure shows significant benefit in persons with heart failure with preserved ejection fraction (HFpEF).
Bottle of spilled aspirin
November 23rd 2021

Experts Urge Caution on Aspirin Use Among Persons With HF Risk

Maggie L. Shaw
A new analysis of data from the HOMAGE study addresses previous mixed results on the use of aspirin among patients who may be at risk of heart failure (HF).
Sacubitril/Valsartan Treatment for HFpEF Shown to Reduce NT-proBNP Levels
November 18th 2021

Sacubitril/Valsartan Treatment for HFpEF Shown to Reduce NT-proBNP Levels

Maggie L. Shaw
Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure with preserved ejection fraction (HFpEF).
Adriaan Voors, MD, University Medical Center Groningen, the Netherlands
November 16th 2021

Dr Adriaan Voors Discusses Initiating SGLT2 Inhibitors During Hospitalization

Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, addresses the lack of prescribing for sodium-glucose co-transporter 2 (SGLT2) inhibitors during hospitalization for acute heart failure by highlighting their benefits and that they are part of guideline-directed treatment.
Heart and stethoscope
November 10th 2021

Mortality Increase Seen in Patients With Heart Failure, Hypercapnia

Maggie L. Shaw
Outcomes of in-hospital mortality, 7-day mortality, and emergency department length of stay were investigated among a cohort of patients with acute heart failure and hypercapnia, or excessive levels of CO2 in the blood.
Heart function graphic
November 2nd 2021

Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI

Maggie L. Shaw
Individuals with a history of acute myocardial infarction (AMI), or heart attack, may benefit on several fronts following early administration of the neprilysin inhibitor/angiotensin receptor blocker sacubitril/valsartan.
heart
October 29th 2021

Social Vulnerability Linked to Premature Cardiovascular Deaths

Laura Joszt, MA
The counties in the United States with more social vulnerabilities had higher premature mortality related to cardiovascular diseases, such as heart disease, stroke, high blood pressure, and heart failure.
Picture of a thin and an obese body
October 27th 2021

Obesity Shown to Adversely Influence Heart Health Prior to Symptom Onset

Maggie L. Shaw
For 3 categories of evaluation, elevated cardiac troponin I levels most influenced the development of myocardial injury among persons at higher lifetime weight totals.
white pills coming out of bottle
October 13th 2021

Older Adults Should Not Take Aspirin to Prevent Heart Disease, USPSTF Recommends

Hayden E. Klein
The task force determined that potential harms of adults aged 60 and older using aspirin for prevention outweighed the benefits.
SGLT2 Inhibitors, GLP-1 RAs Featured in Prevention Guidelines
October 4th 2021

SGLT2 Inhibitors, GLP-1 RAs Featured in Prevention Guidelines

Mary Caffrey
The prevention document, released during ESC Congress 2021, marked the first update of this section of the guidelines in 8 years. It featured changes that reflect the arrival of a pair of drug classes with proven benefits in CV outcomes but that experts say are underutilized.
Blood pressure cuff
October 3rd 2021

Higher Odds of Hypertension Seen in Older Women, Younger Men

Hayden E. Klein
New research presented at the AHA Hypertension Scientific Sessions 2021 showed that men aged 20 to 49 years and women 70 and older both had a greater risk of hypertension.
<1
...
34567891011
...
20>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo